https://www.selleckchem.com/pr....oducts/Gefitinib.htm
A new series of triazolopyrimidines and thiazolopyrimidine hydrobromides was designed and prepared as topoisomerase II inhibitors. Screening of all synthesized compounds was carried out by the National Cancer Institute (NCI) of USA. Activity against 60 human cancer cell lines representing different cancer types was determined. Accordingly, compound 3d was the most potent inhibitor especially against the renal cell line A498 causing 92.46% inhibition (IC50 = 3.5 μM). Moreover, cell cycle analysis showed cell cycle arrest caused by comp
Aimer
Commentaire
Partagez
